Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Independent Advisor Alliance grew its position in Insulet Co. (NASDAQ:PODD – Free Report) by 20.8% in the 4th quarter, ...

Shares of Insulet Corp. PODD slid 5.93% to $266.68 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.37% ...

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy ...

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance ...

Insulet stock opened at $270.81 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market cap of $19.02 billion, a P/E ...

Click here to discover the nuances of Insulet with our detailed analytical report. NasdaqGS:PODD Revenue & Expenses Breakdown as at Mar 2025 Insulet (NasdaqGS:PODD) has rewarded its shareholders ...

Insulet (PODD) reported $597.5 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 17.2%. EPS of $1.15 for the same period compares to $1.40 a year ago.